Advertisement

Fatty Acid Cyclooxygenase Metabolism of Arachidonic Acid in Human Tumor Cells

  • W. C. Hubbard
  • M. C. Alley
  • T. L. McLemore
  • M. R. Boyd
Chapter
Part of the Developments in Oncology book series (DION, volume 67)

Abstract

The prostaglandins, leukotrienes and related eicosanoids have been implicated as mediators in human malignant disease, particularly in cellular events related to tumor metastasis, cell proliferation, tumor promotion and host immunoregulation (1–23). There is substantial evidence that human tumor cells may synthesize significant quantities of prostaglandins. Elevated production of prostaglandin E2 (PGE2) has been demonstrated in lung cancer patients in vivo (24,25). Other studies have shown that prostanoid biosynthesis is elevated in human tumor tissues in comparison with production in normal human tissues (26–28) and that cultured human tumor cells synthesize significant quantities of prostanoids (29–32). In the present studies, the profiles of prostanoid biosynthesis from endogenous arachidonic acid in 55 established cell lines derived from human tumors of the colon, lung, prostate, ovary, kidney, and the central nervous system were determined. The objective of these studies was the determination of PGH synthase activity in diverse histological classes of human tumor cells in order to discern whether fatty acid cyclooxygenase metabolism of arachidonic acid may be uniquely characteristic of certain histological classes of human tumors.

Keywords

Human Tumor Cell Small Cell Carcinoma Established Cell Line Adenosquamous Carcinoma Relate Lipid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Honn, K.V., Bockmann, R. S. and Marnett, L. J. Prostaglandins, 21: 833–850, 1981 .PubMedCrossRefGoogle Scholar
  2. 2.
    Rolland, P. H., Martin, P. M., Jacquemier, J., Rolland, A. M. and Toga, M. J. Natl. Cancer Inst., 64: 1061–1070, 1980.Google Scholar
  3. 3.
    Bennett, A., Charlier, E. M., McDonald, E. M., Simpson, J. S., Stanford, I. F. and Zebro, T. Lancet, 2: 624, 1977.PubMedCrossRefGoogle Scholar
  4. 4.
    Bennett, A. In: Practical Applications of Prostaglandins and Their Synthesis Inhibitors (Ed. S. M. M. Karim), MTP Press, Lancaster, United Kingdom, 1979, pp. 149-188.Google Scholar
  5. 5.
    Bennett, A. In: Endocrinology of Cancer, Vol. 3 (Ed. D. P. Rose), CRC Press, Boca Raton, FL, 1982, pp. 113-126.Google Scholar
  6. 6.
    Honn, K. V., Busse, W. D. and Sloane, B. F. Biochem. Pharmacol ., 32; 1–11, 1983.PubMedCrossRefGoogle Scholar
  7. 7.
    Sydney, E. and Salmon, M. D. In: Prostaglandins and Cancer: First International Conference (Eds. T. Powles, T. J. Bockman, K. V. Honn and P. Ramwell), Alan R. Liss, New York, 1984, pp. 633-651.Google Scholar
  8. 8.
    Meerpohl, H. G., Bauknecht, T., Tritschler, V. and Lang, H. In: International Workshop: Heterogeneity of Mononuclear Phagocytes (Ed. W. Forster), Academic Press, New York, 1981, pp. 428-461.Google Scholar
  9. 9.
    Walker, C, Kristensen, F., Bettens, F. and DeWeck, A. L. J. Immunol., 130: 1770–1778, 1983.PubMedGoogle Scholar
  10. 10.
    Young, M. R. and Henderson, S. Immunol. Commun., 11: 345–352, 1982.PubMedGoogle Scholar
  11. 11.
    Brunda, M. J., Herberman, R. B. and Holden, H. T. J. Immunol, 124: 2682–2688, 1980.Google Scholar
  12. 12.
    Taffet, S. M. and Russell, S. W. J. Immunol., 126: 424–432, 1981 .PubMedGoogle Scholar
  13. 13.
    Bresnick, E., Meunier, P. and Lamden, M. Cancer Lett., 7: 121–124, 1979 .PubMedCrossRefGoogle Scholar
  14. 14.
    Verma, A., Ashendel, C. L. and Boutwell, R. K. Cancer Res., 40: 308–312, 1980.PubMedGoogle Scholar
  15. 15.
    Levine, L. Adv. Cancer Res., 35: 49–52, 1981.PubMedCrossRefGoogle Scholar
  16. 16.
    Fisher, S. M., Mills, G. D. and Slaga, T. J. Carcinogenesis (Long.), 3: 1243–1250, 1982.CrossRefGoogle Scholar
  17. 17.
    Levine, L. In: Prostaglandins and Related Lipids, Vol. 2 (Eds. T. J. Powles, R. S., Bockmann, K. V. Honn and P. W. Ramwell), Alan R. Liss, New York, 1984, pp. 189-205.Google Scholar
  18. 18.
    Furstenberger, G., Gross, M. and Marks, F. In: Prostaglandins and Related Lipids, Vol. 2, (Eds. T. J. Powles, R. S. Bockmann, K. V. Honn and P. W. Ramwell), Alan R. Liss, New York, 1984, pp. 239-251.Google Scholar
  19. 19.
    Fischer, S. M. and Slaga, T. J. In: Prostaglandins and Related Lipids, Vol. 2 (Eds. T. J. Powles, R. S. Bockmann, K. V. Honn and P. W. Ramwell), 1984, pp. 255-261.Google Scholar
  20. 20.
    Fischer, S. M. In: Icosanoids and Cancer (Eds. H. Thaler-Dao, A. Crastes de Paulet and R. Paoletti), Raven Press, New York, 1984, pp. 79-90.Google Scholar
  21. 21.
    Furstenberger, G., Gross, M. and Marks, F. In: Icosanoids and Cancer (Eds. H. Thaler-Dao, A. Crastes de Paulet and R. Paoletti), Raven Press, New York, 1984, pp. 91-100.Google Scholar
  22. 22.
    Kato, R. T., Nakadate, T. and Yamamoto, S. In: Icosanoids and Cancer (Eds. H. Thaler-Dao, A. Crastes de Paulet and R. Paoletti), Raven Press, New York, 1984, pp. 101-114 .Google Scholar
  23. 23.
    Levine, L., Goldstein, S. M., Snoek, G. T. and Rigas, A. In: Icosanoids and Cancer (Eds. H. Thaler-Dao,A. Crastes de Paulet and R. Paoletti (eds.), Raven Press, New York, 1984, pp. 115-121 .Google Scholar
  24. 24.
    Seyberth, H. W., Segre, G. V., Morgan, J. L., Sweetman, B. J., Potts, J. T. and Oates, J. A. N. Engl. J. Med., 293: 1278–1283, 1975.CrossRefGoogle Scholar
  25. 25.
    Seyberth, H. W., Segre, B. V., Hamet, P., Sweetman, B. J., Potts, J. T., Jr. and Oates, J. A. Trans. Assoc. Am. Phys., 89: 92–104, 1976.PubMedGoogle Scholar
  26. 26.
    Bennett, A., Carroll, M. A., Stamford, I. F., Whimster, W. F. and Williams, F. Br. J. Cancer, 46: 888–893,1982.PubMedCrossRefGoogle Scholar
  27. 27.
    McLemore, T. L, Hubbard, W. C, Litterst, C. L, Liu, M.C., Miller, S., McMahon, N. A., Eggleston, J. C. and Boyd, M. R. Cancer Res., 48: 3140–3147, 1988.PubMedGoogle Scholar
  28. 28.
    Castelli, M . G . Fanelli, R ., Martelli, Butti, G., Gaetani, P. and Paoletti, P. Cancer Res., 49: 1505–1508, 1989 .PubMedGoogle Scholar
  29. 29.
    Hubbard, W. C, Alley, M. C, McLemore, T. L. and Boyd, M. R. Cancer Res., 48: 2674–2677, 1988.PubMedGoogle Scholar
  30. 30.
    Hubbard, W . C ., Alley, M . C ., McLemore, T . L . and Boyd, M . R . Cancer Res., 48: 4770–4775,1988.PubMedGoogle Scholar
  31. 31.
    Hubbard, W. C, Alley, M. C, McLemore, T. L. and Boyd, M. R. Cancer Res., 49: 826–832, 1989.PubMedGoogle Scholar
  32. 32.
    Lau, S. S., McMahon, J. B., McMenamin, M. G. Schuller, H. M. and Boyd, M. R. Cancer Res., 47: 3757–3762, 1987.PubMedGoogle Scholar
  33. 33.
    Alley, M. C, Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H. and Boyd, M. R. Cancer Res., 48: 598–601, 1988 .Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • W. C. Hubbard
    • 1
  • M. C. Alley
    • 1
  • T. L. McLemore
    • 1
  • M. R. Boyd
    • 1
  1. 1.Program Development Research Group, Division of Cancer TreatmentNational Cancer InstituteFrederickUSA

Personalised recommendations